Lord Abbett & CO. LLC boosted its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 86.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,332,031 shares of the life sciences company's stock after purchasing an additional 618,773 shares during the period. Lord Abbett & CO. LLC owned about 1.73% of Integra LifeSciences worth $30,210,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership grew its holdings in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after acquiring an additional 913 shares in the last quarter. Quadrant Capital Group LLC increased its position in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares during the last quarter. Sterling Capital Management LLC raised its stake in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after purchasing an additional 1,931 shares in the last quarter. Covestor Ltd lifted its holdings in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares during the last quarter. Finally, MetLife Investment Management LLC grew its stake in shares of Integra LifeSciences by 5.3% in the 4th quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock valued at $947,000 after buying an additional 2,111 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on the stock. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $22.71.
Get Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Stock Performance
NASDAQ:IART opened at $16.81 on Friday. The firm has a market capitalization of $1.30 billion, a PE ratio of -186.76, a PEG ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1 year low of $14.45 and a 1 year high of $32.66. The firm's fifty day simple moving average is $20.51 and its 200 day simple moving average is $22.21.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same period last year, the business posted $0.89 earnings per share. The firm's revenue was up 11.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.
Integra LifeSciences Company Profile
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
